白细胞介素-9在哮喘诱导痰中的表达及意义  

Analysis of interleukin-9 in induced sputum from patients with asthma

作　　者：刘政[1] 姚婉贞[2] 丁艳苓[2] 陈燕[3] 

机构地区：[1]中国石油天然气总公司中心医院,河北廊坊065000 [2]北京大学第三医院呼吸科 [3]新疆克拉玛依市中心医院

出　　处：《中国呼吸与危重监护杂志》2006年第6期442-444,431,共4页Chinese Journal of Respiratory and Critical Care Medicine

摘　　要：目的探讨白细胞介素-9(IL-9)在支气管哮喘气道炎症中的作用。方法收集支气管哮喘患者31例,正常对照组15例。用夹心酶联免疫吸附法测定诱导痰上清液IL-9、IL-5及IL-8浓度;用CAP系统通过酶联免疫荧光法测定嗜酸细胞阳离子蛋白(ECP)的浓度。结果哮喘发作期组IL-9、嗜酸粒细胞(EOS)、IL-5和ECP水平明显高于哮喘缓解期组(P均<0·01);哮喘发作期组和缓解期组的IL-9、IL-5、ECP及EOS明显高于正常对照组(P均<0·01)。哮喘发作期组IL-9浓度分别与EOS和IL-5浓度呈正相关(r=0·39,P=0·025;r=0·542,P=0·001),哮喘发作期组IL-8浓度与中性粒细胞百分比呈正相关(r=0·881,P<0·001);在哮喘发作期的中、重度患者中,IL-9与IL-8水平呈正相关(r=0·528,P=0·002)。结论IL-9与哮喘气道内的EOS、IL-5及ECP水平密切相关,在哮喘发作期尤为明显,表明IL-9参与哮喘患者气道炎症过程。Objective To investigate the role of interlenkin-9（IL-9） in the pathogenesis of airway inflammation in asthma. Methods Induced sputum were obtained from 31 asthmatics in acute exacerbation phase and stable phase. 15 healthy individuals were enrolled as controls. IL-9, IL-5 and IL-8 in sputum supernatants were assayed by sandwich enzyme-linked immunosorbent assay（ ELISA）, and eosinoptfilic cationic protein （ECP） was measured with immuno-CAP system. Results The counts of EOS, the levels of IL-9, IL-5 and ECP in induced sputum of the asthmatics were significantly higher than those in the controls（all P 〈 0.01）. Furthermore, these parameters were higher in the asthmatics of acute exacerbation than those of stable phase （P 〈 0.01 for each）. In the acute exacerbated asthmatics, a positive correlation was found between the level of IL-9 and the perceutage of eosinophile （ r = 0.39, P = 0.025）, the level of IL-5 and IL-9（ r = 0.542, P = 0.001）,the level of IL-8 and the percentage of neutrophil（ r = 0.881, P 〈 0.001）,and the level of IL-9 and IL-8（ r = 0.528, P = 0.1302）. Conclusions IL-9 is increased in the induced sputum from asthmatics,especially in exacerbation with asthma, suggesting that IL-9 may participate in the modulation of asthmatic airway inflammation.

关 键 词：白细胞介素-9 哮喘 气道炎症 

分 类 号：R562.25[医药卫生—呼吸系统]